Phase I Study of Irinotecan Liposome (nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of both Unselected and Selected ( for BRCA 1/2 and PALB2 Mutations) Patients with Metastatic Adenocarcinoma of the Pancreas then Followed by a Phase II Study of First Line Treatment of Selected Patients with Metastatic Adenocarcinoma of the Pancreas with Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer»